Sitemap - 2024 - Provectus’s Substack

VisiRose: Provectus’s Founded Entity in Ophthalmology

Provectus Fourth Quarter 2024 Investor Update: Q&A Follow-Up

Provectus Fourth Quarter 2024 Investor Update on November 14th at 2 pm ET Available by Zoom Webinar

All Eyes on Bascom Palmer

Rose Bengal Photodynamic Antimicrobial Therapy for Infectious Keratitis

Provectus Announces Investor Conference Call: November 14th at 2 pm ET

Provectus News Day: October 7, 2024

Provectus News Day: July 4, 2024

Provectus Announces Investor Webinar of 2024 Annual Meeting for June 20th at 4 pm ET

News Day: May 17, 2024

Intralesional Path to Cancer Drug Approval

News Day: April 21, 2024

Stage IV Melanoma: “…the company that saved my life”

Ophthalmology Deal Structure

Building Trust: Bascom Palmer Eye Institute, Provectus Biopharmaceuticals, and RBS PDAT

More Provectus Intellectual Property

Provectus Head and Neck Cancer Poster Presentation at 2024 American Association for Cancer Research Annual Meeting

Provectus Full-Thickness Cutaneous Wound Healing Poster Presentation at 2024 Society for Investigative Dermatology Annual Meeting

Provectus Provides Updated PV-10 Overall Survival Data on Hepatic Metastatic Uveal Melanoma

Audio Recording of Provectus's First Quarter 2024 Conference Call

Provectus First Quarter 2024 Conference Call Script

Provectus Announces First Quarter 2024 Conference Call for February 22nd at 3 pm ET

Provectus Plans Q1 2024 Conference Call

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts